CTOs on the Move

Julius A. Laitin Enterprises

www.julielaitin.com

 
Julius A. Laitin Enterprises is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Sarah Cannon

Sarah Cannon Research Institute is a research organization focusing on therapies for patients including drug development.

Sprout Pharmaceuticals

We re committed to breakthrough firsts in womens sexual health. Novel ideas fuel our entrepreneurial passion. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we re trying to collectively accomplish.

First Dental Health

First Dental Health is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BlueCross BlueShield of Tennessee

As Tennessee`s largest health plan, we`ve been helping Tennesseans find their own unique paths to good health for nearly 70 years. More than that, we`re your neighbors and friends – fellow Tennesseans with deep roots of caring tradition, a focused approach to physical, financial and community good health for today, and a bright outlook for an even healthier tomorrow. Our mission is simple: peace of mind through better health. We`re an independent, not-for-profit, locally governed health plan company – meaning we live and work alongside our Tennessee business customers and plan members. Our 5,500 employees across the state have built our strong reputation for integrity, excellent service and community leadership. But we are also part of the BlueCross BlueShield Association, a nationwide association of health care plans. Because of this, our plan members have access to the same quality health benefits while traveling or living out of state that they have while in Tennessee.

Imagin Medical

Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin`s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.